Global Access Program

Working hand in hand to provide innovative diagnostics solutions to those who need it most

Take Aim Stop Disease

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

Universal access to quality healthcare and medical innovation remains a global challenge.

To address this challenge, many of the world's top relief and aid organizations have joined together with an ambitious goal: to end stop many diseases.

In 2014, Roche launched the Global Access Program to support the UNAIDS 2020 targets to address the HIV/AIDS epidemic. In 2019 the program was expanded to include solutions for other high-burden diseases Tuberculosis (TB), Hepatitis B and C (HBV and HCV), and Human Papillomavirus (HPV). In response to the COVID-19 pandemic, the SARS-CoV-2 test was included into the program in 2021 to enable access to reliable testing for patients in lower- and middle-income countries (LMIC).

Roche continues to partner with national governments, local healthcare facilities, communities and international agencies, including UNAIDS, CHAI, Unitaid, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), Global Fund, and Centers for Disease Control (CDC) to help strengthen health system capacity beyond the provision of diagnostic tests.

HUMAN IMMUNODEFICIENCY VIRUS (HIV)

Join the leading provider of HIV viral load testing as it expands access to diagnostic testing for countries hardest hit by HIV.

TUBERCULOSIS (TB)

Take aim at tuberculosis. The leading killer of HIV-positive people, Roche is committed to working towards the WHO road map to stop this challenging infection.

HUMAN PAPILLOMAVIRUS (HPV)

Roche supports the WHO global strategy to eliminate cervical cancer by 2030 through access to HPV DNA screening for countries with high disease burden.

HEPATITIS B AND C (HBV AND HCV)

Hepatitis B and C are among the most common viral infections in the world. At least 263 million worldwide in 2017 – are carriers of hepatitis B or C virus infections, which can remain asymptomatic for decades.

COVID-19 (SARS-CoV-2)

Roche is deeply committed to supporting the global response to put an end to the COVID-19 pandemic.

Since its inception, the program has expanded substantially in menu and geographic footprint to provide increased access to diagnostics at affordable pricing for qualifying organizations in eligible countries with the highest disease burden.

Roche Diagnostics joins force with nonprofit (RED) organization

Together, as a community, we can emphasize the importance of diagnostic testing as a critical step to reach the goal of an AIDS-free generation by 2030. Meeting UNAIDS elimination goals¹ is impossible without testing.